Therapy Detail

Therapy Name P276-00
Therapy Description

P276-00 is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
P276-00 CDK1 Inhibitor 12 CDK4 Inhibitor 12 CDK9 Inhibitor 11 P276-00 is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable P276-00 Phase I Actionable In a Phase I study, P276-00 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors ( J Clin Oncol (Meeting Abstracts) June 2007 vol. 25 no. 18_suppl 14117). detail...
Clinical Trial Phase Therapies Title Recruitment Status